Next-Generation In Vitro Diagnostics (IVD) Market is Projected to: to Reach $172.02 Billion by 2029

 Crafted for informed planning, this report explores the forces reshaping the next-generation in vitro diagnostics (ivd) market and what they mean for business leaders.

 
 How Much Is The Next-Generation In Vitro Diagnostics (IVD) Market Worth?
 The next-generation in vitro diagnostics (IVD) market size has grown rapidly in recent years. It will grow from $106.97 billion in 2024 to $117.97 billion in 2025 at a compound annual growth rate (CAGR) of 10.3%. The growth in the historic period can be attributed to increasing geriatric population, growth in government funding, increasing investments in genomic research, growth in clinical trials, and rise in consumer health awareness.
 
 The next-generation in vitro diagnostics (IVD) market size is expected to see strong growth in the next few years. It will grow to $172.02 billion in 2029 at a compound annual growth rate (CAGR) of 9.9%. The growth in the forecast period can be attributed to rising development of personalized medicine, increasing healthcare expenditure, increasing research and development activities, rising prevalence of infectious diseases, and increasing chronic disease cases. Major trends in the forecast period include technological innovation, integration of artificial intelligence and machine learning in diagnostics, advanced diagnostic technologies, personalized medicine, and novel biomarker development.
 
 Get your free sample today:
 https://www.thebusinessresearchcompany.com/sample.aspx?id=25848&type=smp
 
 What Are The Current Leading Growth Drivers For Next-Generation In Vitro Diagnostics (IVD) Market?
 The increasing demand for personalized medicine is expected to propel the growth of the next-generation in vitro diagnostics (IVD) market going forward. Precision medicine is a healthcare approach that customizes disease prevention and treatment based on an individual’s genetic profile, environment, and lifestyle. Personalized medicine is rising due to the growing availability of genomic data, which allows healthcare providers to design targeted treatments based on a person’s unique genetic makeup, leading to more effective care. Next-generation in vitro diagnostics (IVD) supports personalized medicine by providing precise molecular and genetic insights that enable tailored treatment and prevention strategies for individual patients. For instance, in February 2024, according to the Personalized Medicine Coalition, a US-based hospital and health care organization, in 2023, the FDA approved 16 new personalized treatments for rare disease patients, up from six in 2022. Therefore, the increasing demand for personalized medicine is driving the growth of the next-generation in vitro diagnostics (IVD) market.
 
 Which Segment Accounted For The Largest Next-Generation In Vitro Diagnostics (IVD) Market Share?
 The next-generation in vitro diagnostics (ivd) market covered in this report is segmented — 
 
 1) By Product Type: Consumables, Instruments, Software
 2) By Type: Core Laboratory Diagnostics, Point-Of-Care Testing, Molecular Diagnostics
 3) By Application: Oncology Or Cancer, Infectious Diseases, Diabetes, Cardiology , Other Applications
 4) By End-User: Hospitals And Clinics, Diagnostic Laboratories, Academic And Research Institutions, Other End Users
 
 Subsegments:
 1) By Software: Laboratory Information Management Systems, Specimen Tracking Software Modules, Cloud-Based Tracking Software, Barcode and Radio Frequency Identification Integration Platforms, Mobile Applications for Specimen Tracking
 2) By Consumables: Barcode Labels, Radio Frequency Identification Tags, Specimen Bags and Tubes, Labeling Ribbons, Seals and Caps
 3) By Hardware: Barcode Scanners, Radio Frequency Identification Readers, Label Printers, Workstations and Terminals, Storage and Transport Monitoring Devices
 
 
 Next-Generation In Vitro Diagnostics (IVD) Market Emerging Trends And Opportunities
 Major companies operating in the next-generation in vitro diagnostics (IVD) market are adopting A strategic partnerships approach in next-generation in vitro diagnostics involves collaborating with technology providers, research institutions, and healthcare organizations to accelerate innovation, enhance diagnostic accuracy, and expand access to advanced testing solutions for individuals, businesses, and governments. Strategic partnerships refer to a process in which companies leverage each other’s strengths and resources to achieve mutual benefits and success. For instance, in October 2024, Yourgene Health, a UK-based biotechnology company, partnered with Genetix, a Colombia-based human genetic diagnosis company, to launch Colombia’s first local non-invasive prenatal testing (NIPT) service. This initiative represents a significant advancement in prenatal care in the region, offering expectant parents faster, more reliable, and cost-effective access to advanced genetic screening. The service utilizes Yourgene Health’s IONA Nx NIPT Workflow, a comprehensive, CE-marked in vitro diagnostic (IVD) solution. This workflow is highly flexible and scalable, suitable for varying sample volumes, and enables Genetix to offer a quality-assured prenatal screening service within Colombia
 
 Which Are The Top Companies To Hold The Market Share In Next-Generation In Vitro Diagnostics (IVD) Market?
 Major companies operating in the next-generation in vitro diagnostics (ivd) market are F Hoffmann-La Roche AG, Thermo Fisher Scientific Inc., Abbott Laboratories, Becton Dickinson and Company, Quest Diagnostics Incorporated, Grifols SA, Agilent Technologies Inc., Illumina Inc., Sysmex Corporation, Bio-Rad Laboratories Inc., Revvity Inc., Exact Sciences Corporation, QIAGEN NV, DiaSorin SpA, Singular Genomics Systems Inc., Guardant Health Inc., Pacific Biosciences of California Inc., Transasia Bio-Medicals Ltd., Athena Dx, J Mitra and Co Pvt Ltd 
 
 View the full next-generation in vitro diagnostics (ivd) market report here:
 https://www.thebusinessresearchcompany.com/report/next-generation-in-vitro-diagnostics-ivd-global-market-report
 
 Which Region Is Projected To Account For The Largest Share Of The Next-Generation In Vitro Diagnostics (IVD) Market?
 North America was the largest region in the next-generation in vitro diagnostics (IVD) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the next-generation in vitro diagnostics (ivd) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
 
 Contact Us:
 
 The Business Research Company 
 
 https://thebusinessresearchcompany.com/ 
 
 Americas +1 310–496–7795
 Asia +44 7882 955267 & +91 8897263534
 Europe +44 7882 955267 
 
 Email: info@tbrc.info 
 
 
 Follow Us On:
 
 LinkedIn: https://in.linkedin.com/company/the-business-research-company